Additional Relevant Details Medivation announced that the FDA accepted for review a "supplemental New Drug Application (sNDA) that they have submitted for XTANDI (enzalutamide) capsules in metastatic castration-resistant prostate cancer (mCRPC), which includes findings from the Phase 2 TERRAIN and STRIVE studies, to update the relevant clinical sections within the current indication. "  PDUFA decision date was set on October 22, 2016.